BIOPIRACY CASES AND LEGAL RESPONSE

This Article is written by Aanchal Tiwari, Maharaja Agrasen Institute of Management Studies, an intern under Legal Vidhiya.

ABSTRACT

This article investigates the phenomenon of biopiracy, defined as the unauthorized appropriation of biological resources and traditional knowledge from indigenous communities by commercial entities. It analyzes landmark legal battles regarding Turmeric, Neem, and Basmati rice to illustrate the conflict between intellectual property regimes and indigenous rights. Furthermore, the paper examines the evolution of the international legal framework, specifically the conflict between the TRIPS Agreement and the Convention on Biological Diversity (CBD). It delves into India’s domestic legislative response, highlighting the Divya Pharmacy judgment and the Traditional Knowledge Digital Library (TKDL). The study concludes by identifying emerging threats such as Digital Sequence Information (DSI) and advocating for a harmonized legal approach that mandates disclosure of origin in patent applications to ensure equitable benefit sharing.

KEYWORDS

Biopiracy, Traditional Knowledge,  Patent Law, Biological Diversity, Nagoya Protocol, Divya Pharmacy, Benefit Sharing

INTRODUCTION

The intersection of biotechnology, intellectual property, and indigenous heritage has given rise to one of the most contentious issues in modern international law: biopiracy. This term refers to the appropriation of biological resources and associated traditional knowledge (TK) from developing nations by corporations or researchers from developed countries, often without obtaining prior informed consent or providing fair compensation. For centuries, indigenous communities have nurtured biodiversity and developed complex systems of knowledge regarding the medicinal and agricultural properties of plants. However, in the era of globalization, this knowledge is frequently treated as raw material for the multi-billion dollar pharmaceutical and agricultural industries.

The economic stakes are staggering. It is estimated that a significant percentage of the world’s pharmaceutical products are derived from natural resources, many of which have been used in traditional medicine systems like Ayurveda, Siddha, and Unani for generations. When a corporation patents a derivative of a plant used for centuries by indigenous people, it not only commodifies a shared heritage but often restricts the community’s right to use their own resources. This creates a severe equity gap, known as the “North-South” divide, where the biodiversity-rich Global South provides the raw material, while the technology-rich Global North captures the value through the patent system.

The legal dilemma arises from the clash between the patent systems of the industrialized world, which reward “novelty,” “inventive step,” and “industrial application,” and the communal, oral traditions of indigenous populations. Western intellectual property (IP) regimes view knowledge as the property of an individual creator, protected for a limited time. In contrast, Traditional Knowledge (TK) is intergenerational, often community-owned, and evolves constantly, making it difficult to fit into the rigid criteria of modern patent law. This incompatibility creates a loophole a “terra nullius” of the mind where corporations claim ownership over “discoveries” that are actually common knowledge in the source community.

This article seeks to explore the legal landscape of biopiracy by examining high-profile cases that have shaped global consciousness. It will analyze the legal mechanisms used to challenge these patents, evaluate the effectiveness of current international frameworks like the Nagoya Protocol, and discuss the emerging threat of “Digital Biopiracy.” By understanding the historical context and legal precedents, we can better assess the ongoing efforts to protect traditional knowledge in a digital age.

UNDERSTANDING BIOPIRACY: THEFT OR INNOVATION?

To understand the legal ramifications of biopiracy, one must first distinguish it from legitimate bioprospecting. Bioprospecting involves the search for plant and animal species that may possess medicinal or commercial value, conducted within a framework of legal compliance, ethical standards, and benefit-sharing agreements. Biopiracy occurs when this process bypasses the sovereign rights of nations and the intellectual property of indigenous communities.

The crux of the issue lies in the patent system’s requirement for “novelty” and “non-obviousness.” Often, patent examiners in the United States or Europe grant patents for “inventions” that are merely minor modifications of ancient practices. This happens largely because traditional knowledge is often oral and undocumented in the “prior art” databases that Western examiners consult. If an examiner cannot find a written record of a specific plant use in a scientific journal, they may erroneously conclude that the corporate claim is a novel invention.

This systemic failure allows for the privatization of public goods. For example, if a tribe has used a specific root to cure headaches for centuries, and a pharmaceutical company isolates the active compound and patents it without modifying it significantly, they have essentially privatized a public domain resource. This acts as a double burden on the developing nation: they lose ownership of the resource and must eventually pay royalties to buy back the medicine derived from their own heritage.

LANDMARK CASES OF BIOPIRACY

The legal evolution against biopiracy has been driven largely by reactive litigation. Several high-profile cases involving Indian biological resources served as a wake-up call for the developing world, highlighting the vulnerability of traditional knowledge to foreign patent regimes.

The Turmeric Case: Establishing Oral Tradition as Prior Art

One of the earliest and most significant victories against biopiracy involved the patenting of turmeric (Curcuma longa). In 1995, the United States Patent and Trademark Office (USPTO) granted a patent to two expatriate Indians at the University of Mississippi Medical Center for the “use of turmeric in wound healing.”¹ The claim covered the administration of turmeric powder for healing surgical wounds and ulcers. In India, the use of turmeric as an antiseptic and distinct healing agent has been a household practice for millennia, documented in ancient Ayurvedic texts.

The Council of Scientific and Industrial Research (CSIR) in India challenged the patent. The legal battle hinged on the definition of “prior art.” The CSIR had to prove that the “invention” was already known to the public. However, US law at the time largely recognized prior art only if it was in print. The CSIR painstakingly collected ancient Sanskrit texts and papers published in 1953 in the Journal of the Indian Medical Association, which clearly documented turmeric’s healing properties.²

Based on this overwhelming evidence, the USPTO revoked the patent in 1997. This case was a landmark not just because the patent was cancelled, but because it forced the USPTO to recognize that traditional knowledge, even if not published in Western journals, constitutes prior art. It exposed the “blind spot” in the American patent examination process regarding non-Western knowledge systems.

The Neem Case: The Struggle over the “Village Pharmacy”

The Neem tree (Azadirachta indica) is culturally ubiquitous in India, used for everything from teeth cleaning to pest control. In the early 1990s, the chemical giant W.R. Grace and the US Department of Agriculture were granted a patent by the European Patent Office (EPO) for a method of controlling fungi on plants by using oil extracted from neem seeds.³

W.R. Grace argued that their patent was legitimate because their extraction method stabilized the azadirachtin (the active ingredient) for a longer shelf life, which they claimed was a “novel” improvement over the traditional method used by Indian farmers. Indian activists, led by Dr. Vandana Shiva and the Research Foundation for Science, Technology and Ecology, challenged this, arguing that the fungicidal properties of neem were public knowledge and the stabilization techniques were obvious extensions of known chemistry.

The legal opposition lasted ten years. The opponents provided evidence that Indian farmers had been using neem extracts for pest control for centuries. In a historic ruling, the EPO revoked the patent in 2000, stating that the invention lacked an “inventive step.”⁴ The revocation was upheld in 2005. This case was crucial in establishing that minor chemical tweaks to traditional practices do not constitute a patentable invention. It demonstratd that the “inventive step” threshold must be strictly applied to prevent the monopolization of traditional resources.

The Basmati Rice Case: Protecting Geographical Identity

Perhaps the most commercially sensitive case involved Basmati rice, a long-grain aromatic rice grown in the Punjab region of India and Pakistan. In 1997, a Texas-based company, RiceTec Inc., was granted a patent by the USPTO for “Basmati rice lines and grains.” The patent allowed RiceTec to sell rice grown in the US under the brand “Kasmati” or “Texmati” while claiming it was superior to traditional Basmati.⁵

This posed a direct economic threat to Indian exports, valued at hundreds of millions of dollars. The Indian government intervened, challenging specific claims in the patent that were deemed too broad. India argued that “Basmati” is a Geographical Indication (GI) a product inextricably linked to a specific region much like “Champagne” is to France. While the USPTO did not revoke the entire patent, RiceTec was forced to withdraw several key claims, including the right to call their rice “Basmati” generically.⁶ This case underscored the complexities of protecting not just genetic material but also the reputation and market identity associated with traditional crops.

INTERNATIONAL LEGAL FRAMEWORKS: CONFLICT AND EVOLUTION

The outcry over these cases catalyzed a shift in international law. Prior to the 1990s, biological resources were largely considered the “common heritage of mankind,” freely available for exploitation. This paradigm shifted with the adoption of the Convention on Biological Diversity (CBD).

The Convention on Biological Diversity (CBD)

Adopted in 1992, the CBD marked a turning point by asserting that states have sovereign rights over their own biological resources.⁷ It established three main goals: the conservation of biological diversity, the sustainable use of its components, and the fair and equitable sharing of benefits arising from genetic resources. Article 15 of the CBD explicitly recognizes the authority of national governments to determine access to genetic resources, subjecting such access to “Prior Informed Consent” (PIC) and “Mutually Agreed Terms” (MAT).⁸ This moved the legal baseline from free access to regulated exchange, mandating that bioprospectors must get permission and share profits.

The TRIPS Agreement vs. CBD

A major legal tension exists between the CBD and the World Trade Organization’s TRIPS Agreement. The TRIPS Agreement sets global minimum standards for intellectual property protection. Article 27.3(b) of TRIPS allows member countries to exclude plants and animals from patentability but requires them to provide protection for plant varieties either by patents or by an effective sui generis system.⁹

Critics argue that TRIPS promotes the privatization of genetic resources, essentially allowing patents on life forms, which potentially contradicts the CBD’s mandate for benefit-sharing. While the CBD emphasizes community rights and sovereignty, TRIPS emphasizes private property rights. Developing nations have long pushed for an amendment to TRIPS that would require patent applicants to disclose the origin of biological resources and prove they obtained Prior Informed Consent. However, developed nations, particularly the US, have resisted this, arguing it would burden the patent system.

The Nagoya Protocol: Operationalizing Benefit Sharing

To resolve some of these tensions and operationalize the CBD, the Nagoya Protocol was adopted in 2010. The Protocol provides a transparent legal framework for the “Access and Benefit Sharing” (ABS) mechanism.¹⁰ It creates incentives to conserve genetic resources by requiring users (such as pharmaceutical researchers) to comply with the domestic legislation of the provider country. It obligates countries to set up “checkpoints” to monitor the utilization of genetic resources, ensuring that biopiracy can be tracked and penalized across borders.

INDIA’S DOMESTIC LEGAL RESPONSE

As a mega-diverse nation, India has been proactive in establishing a domestic legal shield to comply with the CBD and protect its heritage.

The Biological Diversity Act, 2002

India enacted the Biological Diversity Act (BDA) in 2002. The Act establishes a three-tiered structure: the National Biodiversity Authority (NBA) at the center, State Biodiversity Boards (SBBs) at the state level, and Biodiversity Management Committees (BMCs) at the local level.¹¹ Section 6 of the Act prohibits anyone from applying for any intellectual property right in or outside India for any invention based on research or information on a biological resource obtained from India without obtaining the previous approval of the NBA. This statutory provision acts as a gatekeeper.

The Divya Pharmacy Judgment (2018)

A landmark moment in Indian environmental jurisprudence occurred in Divya Pharmacy v. Union of India (2018). Divya Pharmacy, a branch of Yoga Guru Ramdev’s Patanjali Yogpeeth, challenged the Uttarakhand State Biodiversity Board’s demand for a “Fair and Equitable Benefit Sharing” (FEBS) fee. The company argued that as an Indian entity, it was not liable to share benefits under the Biological Diversity Act, claiming the Act only targeted foreign entities to prevent biopiracy.

The Uttarakhand High Court rejected this argument. In a progressive interpretation of the law, the Court ruled that the concept of FEBS is not limited to foreign entities. It held that indigenous and local communities are the “real custodians” of biological resources, and even domestic companies must share their commercial profits with these communities.¹² This judgment expanded the definition of biopiracy to potentially include domestic exploitation, ensuring that local tribes and farmers are compensated regardless of the nationality of the corporation.

The Traditional Knowledge Digital Library (TKDL)

Perhaps India’s most innovative legal tool is the Traditional Knowledge Digital Library (TKDL). Realizing that patents on turmeric and neem were granted because examiners could not read Sanskrit, India digitized its ancient texts.¹³ The TKDL breaks the language barrier by providing scientifically structured information on traditional knowledge in five international languages (English, German, French, Japanese, and Spanish). This database is accessible to major patent offices globally, including the USPTO and EPO. By establishing prior art in a language examiners can understand, the TKDL acts as a defensive mechanism, preempting biopiracy before a patent is even granted. It has successfully resulted in the withdrawal or cancellation of dozens of patent applications without the need for costly litigation.

A SUCCESSFUL MODEL: THE KANI TRIBE CASE

While litigation is one tool, benefit-sharing models offer a proactive solution. The case of the Kani tribe in Kerala is often cited as a global model for ABS. Scientists from the Tropical Botanic Garden and Research Institute (TBGRI) discovered that the Kani men remained energetic during long treks by chewing the leaves of a plant called Arogyapacha (Trichopus zeylanicus).

Based on this traditional knowledge, the scientists developed a drug named “Jeevani.” Unlike typical biopiracy cases, the institute decided to share the commercial benefits. A trust was established for the Kani people, and 50% of the license fee and royalties received from the pharmaceutical company were transferred to the community.¹⁴ While there were implementation challenges, this case demonstrated that it is possible to commercialize traditional knowledge while respecting and rewarding the original custodians.

EMERGING THREATS: DIGITAL BIOPIRACY

As technology evolves, so does biopiracy. The latest challenge is “Digital Sequence Information” (DSI). Today, researchers can sequence the genome of a plant and upload the data to the internet. A scientist in another country can download this genetic code and synthesize the protein or active compound in a lab without ever physically touching the plant or visiting the country of origin.¹⁵

Because the CBD and Nagoya Protocol largely apply to physical access to genetic resources, DSI falls into a legal grey area. Developing nations argue that DSI should be subject to benefit-sharing obligations, while developed nations argue that restricting data flow would hinder scientific progress. This “dematerialization” of genetic resources represents the new frontier of biopiracy, requiring urgent updates to international law.

CONCLUSION

Biopiracy represents a modern form of colonialism, where the intellectual and biological wealth of the marginalized is extracted for the profit of the privileged. The legal battles over Turmeric, Neem, and Basmati were not merely disputes over plants; they were assertions of cultural sovereignty and the right to self-determination.

While the international legal framework has evolved significantly from the “common heritage” doctrine to the sovereign rights approach of the CBD and Nagoya Protocol, challenges remain. The conflict between the private rights championed by TRIPS and the collective rights advocated by the CBD continues to create legal uncertainty. Furthermore, the rise of Digital Sequence Information threatens to render physical border controls obsolete.

For a truly equitable global system, patent laws must be harmonized to mandate the disclosure of the source of origin and proof of benefit-sharing in all biotechnological applications. Additionally, courts must continue to interpret domestic laws expansively, as seen in the Divya Pharmacy case, to ensure that the “real custodians” of nature the indigenous communities are partners in progress, rather than victims of piracy. Only through a robust legal architecture that respects both innovation and tradition can we ensure the sustainable and equitable use of the planet’s biodiversity.

REFERENCES

1. U.S. Patent No. 5,401,504 (issued Mar. 28, 1995).
2. Suman Sahai, The Bogus Debate on Bio-piracy, 36 Econ. & Pol. Wkly. 3661, 3662 (2001).
3. Eur. Patent No. 0436257 (issued Sept. 14, 1994).
4. Vandana Shiva, The Neem Tree: A Case History of Biopiracy, Third World Network (Apr. 24, 2005), https://www.twn.my.
5. U.S. Patent No. 5,663,484 (issued Sept. 2, 1997).
6. Dwijen Rangnekar, Indications of Geographical Origin in Asia: Legal and Policy Issues to Resolve, in Intellectual Property and Sustainable Development 273 (Melendez-Ortiz & Roffe eds., 2009).
7. Convention on Biological Diversity art. 3, June 5, 1992, 1760 U.N.T.S. 79.
8. Id. at art. 15.
9. Agreement on Trade-Related Aspects of Intellectual Property Rights art. 27.3(b), Apr. 15, 1994, 1869 U.N.T.S. 299.
10. Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity, Oct. 29, 2010, UNEP/CBD/COP/DEC/X/1.
11. The Biological Diversity Act, 2002, No. 18, Acts of Parliament, 2003 (India).
12. Divya Pharmacy v. Union of India, 2018 SCC OnLine Utt 1035.
13. V.K. Gupta, Protecting Indian Traditional Knowledge from Biopiracy, 1 J. Intell. Prop. Rts. 21 (2011).
14. R.V. Anuradha, Sharing the Benefits of Biodiversity: The Kani-TBGRI Deal in Kerala, India, Kalpavriksh (2000).
15. Margo A. Bagley, De-Materializing Genetic Resources: Synthetic Biology, Intellectual Property and the ABS Loophole, 59 Va. J. Int’l L. 209 (2019).

Disclaimer: The materials provided herein are intended solely for informational purposes. Accessing or using the site or materials does not establish an attorney-client relationship. The information presented on this site is not to be construed as legal or professional advice, and it should not be relied upon for such purposes or used as a substitute for advice from a licensed attorney in your state. Additionally, the viewpoint presented by the author is personal.

Hitesh Prajapat